跳轉至內容
Merck
全部照片(1)

重要文件

324905

Sigma-Aldrich

Epirubicin Hydrochloride - CAS 56390-09-1 - Calbiochem

A cell-permeable antitumor antibiotic.

同義詞:

Epirubicin Hydrochloride - CAS 56390-09-1 - Calbiochem, 4ʹ-Epidoxorubicin, HCl

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C27H29NO11 · xHCl
CAS號碼:
分子量::
543.52 (free base basis)
MDL號碼:
分類程式碼代碼:
12352200
暫時無法取得訂價和供貨情況

品質等級

化驗

≥95% (HPLC)

形狀

solid

製造商/商標名

Calbiochem®

儲存條件

OK to freeze
desiccated (hygroscopic)
protect from light

顏色

orange-red

溶解度

water: 1 mg/mL

運輸包裝

ambient

儲存溫度

2-8°C

InChI

1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1

InChI 密鑰

MWWSFMDVAYGXBV-FGBSZODSSA-N

一般說明

A cell-permeable, antitumor antibiotic. A stereoisomer of doxorubicin that exhibits reduced cardiotoxicity. Its antitumor actions are mediated by targeting topoisomerase II.
This product has been discontinued.

生化/生理作用

Cell permeable: yes
Primary Target
Antitumor antibiotic
Product does not compete with ATP.
Reversible: no

警告

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

重構

Following reconstiution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他說明

Luck, H.J., et al. 1996. Semin. Oncol.23, 33.
Sandri, M.I., et al. 1996. Br. J. Cancer73, 1518.
Boddy, A.V., et al. 1995. Eur. J. Cancer31A, 69.
Pouna, P., et al. 1995. Cancer. Chemother. Pharmacol.35, 257.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險分類

Acute Tox. 4 Oral - Carc. 1B - Muta. 1B - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Ramchandra Vigay Amnekar et al.
World journal of gastroenterology, 26(6), 598-613 (2020-02-28)
The prognosis of gastric cancer continues to remain poor, and epigenetic drugs like histone deacetylase inhibitors (HDACi) have been envisaged as potential therapeutic agents. Nevertheless, clinical trials are facing issues with toxicity and efficacy against solid tumors, which may be

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務